Ari Friedland

Vice President of Research at Typewriter Therapeutics

Speaker

As Vice President of Research at Typewriter Therapeutics, Ari E Friedland is leading the development of in vivo therapeutics via an RNA-only, site-specific gene integration platform. The first scientist to publish heritable genome editing in vivo using CRISPR, Ari has twenty years of research and company-building experience at the forefront of synthetic biology, genome editing, and epigenome editing. At Editas Medicine, where he was among the earliest scientists, Ari was central to the establishment of the company’s gene editing platform and was critical in the design of EDIT-101, an AAV treatment for a rare genetic blindness and the first in vivo CRISPR therapy ever administered to patients. Later, as one of the first employees at Chroma Medicine, Ari played a crucial role establishing its epigenome editing platform and designing CRMA-1001, an LNP formulation targeting Hepatitis B.